Inga Liepelt-Scarfone

Inga Liepelt-Scarfone

Auto-generated profile, based on publicly available information

Inga Liepelt-Scarfone

Hertie Institute for Clinical Brain Research, Tuebingen, Germany 2

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
JUJanet M.T. van Uem
Janet M.T. van Uem
JMJohan Marinus
Johan Marinus
CCColleen Canning
Colleen Canning
RLRob Van Lummel
Rob Van Lummel
RDRichard Dodel
Richard Dodel
WMWalter Maetzler
Walter Maetzler

13 June 2018 in Journal of Parkinson’s Disease
Verified
Journal Article
Open access
PDF file
MRMandy Roheger
Mandy Roheger
EKElke Kalbe
Elke Kalbe
ILInga Liepelt-Scarfone
Inga Liepelt-Scarfone
Background: Cognitive dysfunction is one of the most prevalent non-motor symptoms in Parkinson’s disease (PD), often experienced as more debilitating for patients and caregivers than motor problems. Therefore, a deeper understanding of the course of

9 October 2013 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
KKKathrin N Karle
Kathrin N Karle
RSRebecca Schuele
Rebecca Schuele
SKStephan Klebe
Stephan Klebe
SOSusanne Otto
Susanne Otto
CFChristian Frischholz
Christian Frischholz
Ludger SchoelsLudger Schoels
Ludger Schoels
Background: Hereditary spastic paraplegias (HSPs) are characterised by lower limb spasticity due to degeneration of the corticospinal tract. We set out for an electrophysiological characterisation of motor and sensory tracts in patients with HSP. Methods: We clinically and electrophysiologically examined a cohort of 128 patients with genetically confirmed or clinically probable HSP. Motor evoked potentials (MEPs) to arms and legs, somato-sensory evoked potentials of median and tibial nerves, and nerve conduction studies of tibial, ulnar, sural, and radial nerves were assessed. Results: Whereas all patients showed clinical signs of spastic paraparesis, MEPs were normal in 27% of patients and revealed a broad spectrum with axonal or demyelinating features in the others. This heterogeneity can at least in part be explained by different underlying genotypes, hinting for distinct pathomechanisms in HSP subtypes. In the largest subgroup, SPG4, an axonal type of damage was evident. Comprehensive electrophysiological testing disclosed a more widespread affection of long fibre tracts involving peripheral nerves and the sensory system in 40%, respectively. Electrophysiological abnormalities correlated with the severity of clinical symptoms. Conclusions: Whereas HSP is primarily considered as an upper motoneuron disorder, our data suggest a more widespread affection of motor and sensory tracts in the central and peripheral nervous system as a common finding in HSP. The distribution patterns of electrophysiological abnormalities were associated with distinct HSP genotypes and could reflect different underlying pathomechanisms. Electrophysiological measures are independent of symptomatic treatment and may therefore serve as a reliable biomarker in upcoming HSP trials.

6 December 2022 in Neurology
Verified
Journal Article
Open access
PDF file
SBSara Becker
Sara Becker
MBMerle Bode
Merle Bode
KBKathrin Brockmann
Kathrin Brockmann
TGThomas Gasser
Thomas Gasser
KMKatja Michaelis
Katja Michaelis
ILInga Liepelt-Scarfone
Inga Liepelt-Scarfone
Background and Objectives One-third of Parkinson disease (PD) patients with PD-mild cognitive impairment (PD-MCI) convert to dementia within a few years. Markers with a high prognostic value for dementia conversion are needed. Loss of everyday function primarily caused by cognitive dysfunction is the core criterion for the diagnosis of PD dementia, with an onset of more complex instrumental activities of daily living (IADL) dysfunction in the prodromal stage. This study evaluated the phenotype associated with cognitive IADL impairment and its predictive value for defining a high-risk group for PD dementia. Methods An observational longitudinal study using cognitive and clinical scores in addition to genetic and CSF biomarkers was conducted. The Functional Activities Questionnaire quotient (cut-off ≥1), indicating more cognitive than motor-driven IADL impairment, defined cognitive IADL impairment status at baseline. Hazard ratios (HRs) were used to compare the impact of baseline classifications on dementia conversion. Results Of 268 patients with PD assessed at baseline, 108 (40.3%) had PD-MCI. After a period of 3.78 ± 0.84 years, 164 (61.2%) patients were reassessed. At follow-up, 93 (56.7%) patients had no cognitive impairment, 54 (32.9%) fulfilled PD-MCI criteria, and 17 (10.4%) had developed dementia. The HR of baseline cognitive IADL impairment (n = 37) for dementia conversion was descriptively higher than for PD-MCI, but highest in patients with both markers (HR = 12.01, 95% CI 4.47–32.22, p < 0.001). In the follow-up sample, nearly half of the patients (n = 10, 47.6%) with baseline classification of cognitive IADL impairment and PD-MCI converted to dementia. Baseline status of cognitive IADL impairment was associated with higher nonmotor burden, worse cognitive performance, and more severe IADL progression over the study period. Discussion The importance of differentiating between cognitive and motor aspects on ADL function in PD and monitoring cognitive ADL impairment in the prodromal stage of dementia is paramount. Patients with PD-MCI and cognitive IADL impairment may be a valuable target group for clinical trials aiming to slow down the development of dementia. Trial Registration Information ClinicalTrials.govNCT03687203. Classification of Evidence This study provides Class II evidence that impairment of cognitive activities of daily living is associated with progression from MCI to dementia among patients with Parkinson disease.

9 August 2024 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
EKElke Kalbe
Elke Kalbe
AFAnn-Kristin Folkerts
Ann-Kristin Folkerts
KWKarsten Witt
Karsten Witt
CBCarsten Buhmann
Carsten Buhmann
ILInga Liepelt-Scarfone
Inga Liepelt-Scarfone
FGfor the German Parkinson’s Guidelines Group
for the German Parkinson’s Guidelines Group
Background and objective: Cognitive impairment and dementia as well as affective disorders are common and debilitating syndromes that develop in people with Parkinson’s disease (PwPD). The authors summarized recommendations for the 2023 updated German guidelines on “Parkinson’s disease” from the German Neurological Society (DGN), focusing on the diagnosis and treatment of these disorders. Methods: The recommendations were based on literature reviews, other relevant guidelines, and expert opinions. Results: Measurements to assess cognitive and affective states were reviewed for psychometric properties, use in routine clinical practice, and availability in German. To improve mild cognitive impairment, cognitive training and physical aerobic training are recommended. To treat Parkinson’s disease (PD)-related dementia, cognitive stimulation (as a non-pharmacological intervention) and acetylcholinesterase inhibitors (AChEIs, i.e., rivastigmine) are recommended. Cognitive behavioral therapy is recommended to treat depression, anxiety, and fear of progression. Physical interventions are recommended to treat depression, fatigue, and apathy. Optimized dopaminergic treatment is the first-line pharmacological strategy recommended to manage depression, apathy, anhedonia, fatigue, and mood swings. Major depression can be additionally treated using venlafaxine or desipramine, while moderate depression can be treated pharmacologically according to its clinical phenotype (psychomotor retardation or agitation) and comorbidities (e.g., sleep disturbances, pain). Venlafaxine and nortriptyline can be used to treat anhedonia, while citalopram can be used for anxiety. Conclusions: In addition to the updated pharmacological treatment options, new insights into recommendations for standardized diagnostics and non-pharmacological interventions were provided for the German health care system. However, more studies are needed to explore the full potential of non-pharmacological interventions to treat and prevent cognitive impairment and affective disorders.

30 November 2020 in Parkinson's Disease
Verified
Journal Article
Open access
PDF file
EKElke Kalbe
Elke Kalbe
AFAnn-Kristin Folkerts
Ann-Kristin Folkerts
AOAnja Ophey
Anja Ophey
CECarsten Eggers
Carsten Eggers
SESaskia Elben
Saskia Elben
ILInga Liepelt-Scarfone
Inga Liepelt-Scarfone
Background. Meta-analyses have demonstrated cognitive training (CT) benefits in Parkinson’s disease (PD) patients. However, the patients’ cognitive status has only rarely been based on established criteria. Also, prediction analyses of CT success have only sparsely been conducted. Objective. To determine CT effects in PD patients with mild cognitive impairment (PD-MCI) on cognitive and noncognitive outcomes compared to an active control group (CG) and to analyze CT success predictors. Methods. Sixty-four PD-MCI patients (age: 67.61 ± 7.70; UPDRS-III: 26.58 ± 13.54; MoCA: 24.47 ± 2.78) were randomized to either a CT group or a low-intensity physical activity CG for six weeks (twice weekly, 90 minutes). Outcomes were assessed before and after training. MANOVAs with follow-up ANOVAs and multiple regression analyses were computed. Results. Both interventions were highly feasible (participation, motivation, and evaluation); the overall dropout rate was 4.7%. Time × group interaction effects favoring CT were observed for phonemic fluency as a specific executive test ( p = 0.018 , η p 2 = 0.092 ) and a statistical trend for overall executive functions ( p = 0.095 , η p 2 = 0.132 ). A statistical trend for a time × group interaction effect favoring CG was shown for the digit span backward as a working memory test ( p = 0.098 , η p 2 = 0.043 ). Regression analyses revealed cognitive baseline levels, education, levodopa equivalent daily dose, motor scores, and ApoE status as significant predictors for CT success. Conclusions. CT is a safe and feasible therapy option in PD-MCI, yielding executive functions improvement. Data indicate that vulnerable individuals may show the largest cognitive gains. Longitudinal studies are required to determine whether CT may also attenuate cognitive decline in the long term. This trial is registered with DRKS00010186.